Zelira Therapeutics Ltd
ZLD
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
8
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing 2025 and beyond: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,670.90 | 42.50 | 0.49% |
| CAC 40 | 7,854.92 | 95.25 | -1.20% |
| DAX 40 | 21,732.05 | 4.85 | 0.02% |
| Dow JONES (US) | 44,421.91 | 122.75 | -0.28% |
| FTSE 100 | 8,583.56 | 90.40 | -1.04% |
| HKSE | 20,545.25 | 327.99 | 1.62% |
| NASDAQ | 19,627.44 | 54.31 | -0.28% |
| Nikkei 225 | 39,130.09 | 610.00 | 1.58% |
| NZX 50 Index | 12,817.98 | 7.66 | 0.06% |
| S&P 500 | 5,994.57 | 45.96 | -0.76% |
| S&P/ASX 200 | 8,414.40 | 35.00 | 0.42% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |